DISPOSITIVOS E MÉTODOS DE USO DO MESMO PARA CONTRACEPÇÃO NÃO HORMONAL
Intravaginal devices with bioactive agents address the limitations of hormonal and copper IUDs by providing effective, hormone-free, and easy-to-use contraception with enhanced sperm inhibition near the cervix, improving upon existing methods with reduced side effects and increased accessibility.
Patent Information
- Application Number
- BR112025024612
- Authority / Receiving Office
- BR · BR
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-11
- Filing Date
- 2024-06-03
- Publication Date
- 2026-11-10
AI Technical Summary
Current contraceptive methods, such as hormonal and copper IUDs, pose health risks and require invasive procedures, while spermicidal products are less reliable and inconvenient, necessitating a safe, easy-to-use, and effective alternative.
Intravaginal contraceptive devices releasing bioactive agents with spermicidal or spermiostatic properties in the vaginal, cervical, and endometrial regions, avoiding hormones and uterine insertion, using a torus-shaped elastomeric body with copper-containing agents for enhanced sperm inhibition.
Provides effective contraception with reduced side effects, accessible emergency use, and improved spermicidal efficacy by positioning agents near the cervix, comparable to copper IUDs but without uterine inflammation, and offering hormonal-free and easy insertion.
Abstract
Description
1 / 50 Devices and methods of use thereof for non-hormonal contraception. CROSS-REFERENCE TO RELATED REQUESTS
[0001] This application claims the benefit of U.S. Provisional Application No. 63 / 501,575, filed May 11, 2023, the disclosure of which is incorporated herein by reference in its entirety. FIELD
[0002] The present disclosure relates to devices and methods for non-hormonal contraception and, in particular, to intravaginal contraceptive devices that include copper as a spermicidal or spermiostatic agent. BACKGROUND
[0003] Current contraceptive options use barrier devices, hormonal approaches, and spermicidal agents. Barrier devices, such as condoms, contraceptive sponges, cervical caps, and diaphragms, are often ineffective due to misuse and are generally less convenient. While hormonal methods, such as oral contraceptive pills, patches, rings, injections, implants, and intrauterine devices (IUDs), are potentially more reliable than barrier methods, they have been associated with an increased risk of breast cancer, cervical cancer, Crohn's disease, ulcerative colitis, lupus, multiple sclerosis, impaired glucose metabolism, reduced bone mineral density, reduced libido, headaches, intermenstrual bleeding, depression, anxiety, and suicide. Hormonal contraceptives that use estrogen also increase the risk of deep vein thrombosis, pulmonary embolism, Petition 870250115808, dated 12 / 16 / 2025, page 5 / 67 2 in 50 are associated with heart attack and stroke. This limits the number of women eligible and willing to use them. Spermicidal products, including compositions such as creams and gels, are less reliable and can be unpleasant or difficult to use. Both the copper IUD and the hormonal IUD require an invasive clinical procedure to be implanted and removed from the uterus. This can be painful, and access to a professional to perform the procedure can be difficult, for example, in developing countries or for those without adequate health insurance.
[0004] Copper IUDs can also cause a foreign body reaction and lead to heavier or more painful periods, a major deterrent for patients.
[0005] Therefore, there is a need for an effective, safe and easy-to-use contraceptive option. SUMMARY
[0006] The present disclosure describes innovative contraceptive devices configured to release an effective amount of at least one bioactive agent with spermicidal or spermiostatic properties into the vaginal region, cervical region, and endometrial region of a subject's female reproductive system when positioned in the vaginal region of the female reproductive system. As presented herein, the term "vaginal region" may refer to the positioning of the device described herein, which is intended to be positioned in the upper part of the vagina, meaning, therefore, that the "vaginal region" may refer to the region between the external os of the cervix and the vaginal introitus. To the extent that a different meaning is attributed to the vaginal region, that meaning would be immediately perceived by a Petition 870250115808, dated 12 / 16 / 2025, page 6 / 67 3 / 50 skilled in the art when analyzing the term in conjunction with the surrounding context and the specific terms of the claim.
[0007] A device described herein can be positioned in the vaginal region (i.e., a muscular canal approximately 5-13 cm long, which may vary from person to person) of the female reproductive system. The vaginal walls are lined by an outer fibrous adventitia; an intermediate layer of smooth muscle and an inner mucous membrane. The middle and inner layers allow the vagina to expand to accommodate the device. When the device is placed in the upper part of the vagina (i.e., near the opening of the cervix), a bioactive agent is released, which impairs the metabolic processes and motility of spermatozoa, thus inhibiting fertilization of the ovum. As presented herein, the vaginal region can be defined as the region between the external os of the cervix and the introitus (opening of the vagina), and the cervical region includes the internal os, the endocervix, the ectocervix, and the external os.As the upper portion of the vagina meets the cervix (that is, the narrow lower portion of the uterus), a bioactive agent can diffuse throughout the vaginal region, from the vaginal region to the cervical region and from there to the endometrial region, preventing a sperm from reaching and / or fertilizing an egg.
[0008] The devices described herein offer advantages over current contraceptive methods. Firstly, the devices can be manufactured without hormones and therefore do not have the side effects associated with hormonal devices such as Nuvaring®; secondly, the devices described herein can be positioned in the vaginal region of the female reproductive system, Petition 870250115808, dated 12 / 16 / 2025, page 7 / 67 4 / 50 not inside the uterus and, as such, do not cause a foreign body reaction or inflammation of the uterine tissue, like copper IUDs; thirdly, unlike copper IUDs, the devices described here can be easily used without the need for clinical implantation; fourthly, the devices described here can be used for emergency contraception up to 120 hours after unprotected sexual intercourse, by a subject in need thereof, which cannot be achieved by Nuvaring®. Furthermore, the devices described here can provide unexpectedly better results by positioning the bioactive agent close to the cervix, but within the vaginal region, allowing maximum interaction between the bioactive agent and the environment of the cervix and vaginal region, and maximizing the spermicidal or spermiostatic efficacy of the device compared to previous devices.The devices described herein allow for unexpectedly improved contraception by maximizing the concentrations of the bioactive agent in three areas (the vaginal region, the cervical region, and the uterus) to create more effective spermicidal or spermiostatic results, without the need to insert a foreign object into an area (i.e., placing an IUD in the uterus) that causes adverse effects such as pain and inflammation, in addition to providing the benefits of a ring positioned in the vaginal region without the use of compounds such as hormones. Consequently, the devices described herein represent an unexpected improvement over prior art devices.
[0009] In certain embodiments, a contraceptive device described herein comprises a torus-shaped elastomeric body and at least one bioactive agent with Petition 870250115808, dated 12 / 16 / 2025, page 8 / 67 5 / 50 spermicidal or spermiostatic properties. The elastomeric body may be permeable or impermeable. In certain embodiments, at least one bioactive agent is present as one or more segments coupled to the elastomeric body. The outer surface of one or more segments may be aligned with the outer surface of the elastomeric body. In certain embodiments, at least one bioactive agent is present as multiple inclusions, where the torus-shaped elastomeric body may be dotted with multiple inclusions that expose the surfaces of at least one exposed bioactive agent. In certain embodiments, multiple inclusions are incorporated within a torus-shaped elastomeric body, where the surfaces of at least one bioactive agent may be partially exposed, unexposed, or a combination thereof. In certain embodiments, the elastomeric body has one or more orifices and a copper wire is inserted within the elastomeric body.In certain embodiments, the elastomeric body has one or more orifices and openings where at least one bioactive agent can be stored as solids or solutions within the opening. A bioactive agent can come into contact with the vaginal environment through its exposed surfaces, a permeable membrane, or a permeable elastomeric body.
[0010] In certain embodiments, at least one bioactive agent comprises copper-containing agents. In certain embodiments, at least one bioactive agent is copper, a copper alloy, or a copper salt. In certain embodiments, at least one bioactive agent is copper. In certain embodiments, the total exposed surface area of copper is about 50–1000 mm². In certain embodiments, copper concentrations in the uterus may Petition 870250115808, dated 12 / 16 / 2025, p. 9 / 67 6 / 50 being approximately 3.0–20 pg / g or approximately 3.0–20.0 pg / ml (dry weight) (and ranges between these values) from day 3 until the time of removal of the contraceptive device described herein (e.g., up to 1 month, up to 6 months, up to 1 year, up to 2 years, up to 3 years, up to 4 years, and up to approximately 5 years) after insertion of the device described herein. In certain embodiments, copper concentrations in the uterus are approximately 0.5–5.0 pg / g or approximately 0.5–5.0 pg / ml (wet weight) from day 3 to year 5 after insertion of a device described herein. In certain embodiments, the concentration of copper in the uterus increases for at least about one week after insertion of the device described herein. In certain embodiments, a device described herein exhibits copper release for at least about one week. In certain embodiments, a device described herein may have a Pearl Index of approximately 0.8–5.0.
[0011] In certain embodiments, a contraceptive device described herein may be co-administered with one or more vaginal health-promoting agents. In certain embodiments, one or more vaginal health-promoting agents are administered before, simultaneously with, or after the administration of a contraceptive device described herein. In certain embodiments, the devices described herein may be used for prophylactic contraception before sexual intercourse. In certain embodiments, the devices described herein may be used for emergency contraception within approximately 10 hours, 12 hours, 20 hours, 24 hours, 48 hours, 72 hours, or 120 hours after unprotected sexual intercourse.
[0012] The manufacturing methods for contraceptive devices are also described here. Petition 870250115808, dated 12 / 16 / 2025, page 10 / 67 7 / 50
[0013] These and other features, aspects and advantages of the present embodiments will be understood with reference to the description, figures and claims attached below. BRIEF DESCRIPTION OF THE DRAWINGS
[0014] Reference will now be made, by way of example, to the attached drawings, which show examples of embodiments of the present application, and in which: Figure 1A is an illustrative example of a female reproductive system in which the methods and devices described here can be applied; Figure 1B shows the regions where copper ions concentrate when using the devices described here, compared to some commercially available devices; Figure 1C shows the positions in a female reproductive system that uses the devices described here, compared to some commercially available devices; Figure 2 shows a contraceptive device exemplified as an intravaginal ring, according to the embodiments of the present disclosure; Figure 3 shows an exemplary intravaginal ring with an incorporated copper-containing agent, according to the embodiments of the present disclosure; Figures 4A-4E show an exemplary intravaginal ring with at least one segment containing copper, according to the embodiments of the present disclosure; Figure 5A shows a cross-sectional view of the exemplary intravaginal ring in Figure 4A, according to the embodiments of the present disclosure; Figure 5B is a perspective view of a segment. Petition 870250115808, dated 12 / 16 / 2025, p. 11 / 67 8 / 50 example containing copper, according to the modalities of the present disclosure; Figure 5C is a cross-sectional view of an exemplary segment containing copper, according to the embodiments of the present disclosure; Figure 6A shows a side view of the intravaginal ring in Figure 4A, according to the embodiments of the present disclosure; Figure 6B shows a cross-sectional view of the intravaginal ring in Figure 6A, according to the embodiments of the present disclosure; Figure 7A shows an embodiment exemplifying an intravaginal ring, according to the embodiments of the present disclosure; Figure 7B shows embodiments exemplifying a molded thermoplastic structure of the intravaginal ring of Figure 7A, according to the embodiments of the present disclosure; Figure 8 is a flowchart illustrating an exemplary method of using a contraceptive device, according to the modalities of the present disclosure.
[0015] Similar reference numbers may have been used in different figures to denote similar components. DETAILED DESCRIPTION
[0016] Innovative contraceptive devices are described here that can be positioned in the vaginal region of the female reproductive system by a subject in need thereof and that, after positioning, release at least one bioactive agent with spermicidal or spermiostatic properties in the vaginal region, the cervical region and the Petition 870250115808, dated 12 / 16 / 2025, page 12 / 67 9 / 50 endometrial region for prophylactic contraception and / or emergency contraception. In certain embodiments, a contraceptive device described herein is an intravaginal ring comprising a torus-shaped elastomeric body and at least one bioactive agent coupled to the elastomeric body. In certain embodiments, at least one bioactive agent is present as multiple dotted inclusions or incorporated into the elastomeric body. In certain embodiments, at least one bioactive agent is present as one or more segments coupled to a torus-shaped elastomeric body. The outer surface of one or more segments may be aligned with the outer surface of the elastomeric body. In certain embodiments, the elastomeric body has one or more orifices and the at least one bioactive agent is placed within the elastomeric body.In certain embodiments, the elastomeric body has one or more orifices and / or openings where at least one bioactive agent can be stored as solids or solutions in the opening. In certain embodiments, a contraceptive device described herein further comprises a barrier.
[0017] In certain embodiments, an intravaginal ring described herein has a cross-sectional diameter of about 3.0–10.0 mm and an outer diameter of about 30–90 mm. In certain embodiments, an intravaginal ring described herein has a cross-sectional diameter of about 4.0–10.0 mm and an outer diameter of about 40–80 mm. In certain embodiments, an intravaginal ring described herein has a cross-sectional diameter of about 4.0–9.0 mm and an outer diameter of about 50–60 mm. In certain embodiments, an intravaginal ring described herein has a cross-sectional diameter of about 5.5–9.0 mm and an outer diameter of Petition 870250115808, dated 12 / 16 / 2025, p. 13 / 67 10 / 50 approximately 55-60 mm. In certain embodiments, an intravaginal ring described herein has a cross-sectional diameter of approximately 5.7-6.1 mm or 6.3-7.5 mm and an outer diameter of approximately 55-60 mm. In certain embodiments, an intravaginal ring described herein has a cross-sectional diameter of approximately 6.35 mm and an outer diameter of approximately 55 mm. In certain embodiments, an intravaginal ring described herein has a cross-sectional diameter of approximately 5.6 mm and an outer diameter of approximately 59.7 mm. In certain embodiments, an intravaginal ring described herein has a cross-sectional diameter of approximately 6.2 mm and an outer diameter of approximately 57.6 mm. In certain embodiments, an intravaginal ring described herein has a cross-sectional diameter of approximately 7.9 mm and an outer diameter of approximately 57.6 mm. In certain embodiments, an intravaginal ring described here has a transverse diameter of approximately 9.0 mm and an outer diameter of approximately 55 mm.In certain embodiments, an intravaginal ring described herein has a transverse diameter of approximately 4.0 mm and an outer diameter of approximately 54 mm. In some embodiments, the inner diameter may be between approximately 25 mm and 70 mm, approximately 35 mm and 55 mm, approximately 40 mm and approximately 60 mm, approximately 25 mm and approximately 35 mm, approximately 35 mm and approximately 70 mm, and in intermediate ranges. In some embodiments, the outer diameter may be between approximately 35 mm and 80 mm, approximately 45 mm and 60 mm, approximately 50 mm and approximately 65 mm, approximately 25 mm and approximately 35 mm, approximately 50 mm and approximately 70 mm, and in intermediate ranges.
[0018] In certain embodiments, an elastomeric body is made of a biocompatible polymeric material, which may be permeable or impermeable. In certain embodiments, Petition 870250115808, dated 12 / 16 / 2025, p. 14 / 67 11 / 50 An elastomeric body is made of silicone. A silicone elastomer can be permeable or waterproof.
[0019] In certain embodiments, at least one bioactive agent is present as multiple inclusions. In certain embodiments, an elastomeric body is dotted with multiple inclusions (see, for example, Figure 3), with the entire surface of the inclusions exposed. In certain embodiments, multiple inclusions are incorporated into an elastomeric body, wherein the surface of the inclusions is partially exposed or not exposed. In certain embodiments, multiple inclusions have a total exposed surface area of about 50–1000 mm². In certain embodiments, multiple inclusions have a total exposed surface area of about 200–600 mm². In certain embodiments, multiple inclusions have a total exposed surface area of about 380–600 mm². In certain embodiments, multiple inclusions have a total exposed surface area of about 380–400 mm². In certain embodiments, multiple inclusions have a total exposed surface area of about 400–500 mm².In certain embodiments, multiple inclusions have a total exposed surface area of approximately 394 mm2. In certain embodiments, multiple inclusions have a total exposed surface area of approximately 425 mm2. In certain embodiments, multiple inclusions have a total exposed surface area of approximately 473 mm2.
[0020] In certain embodiments, at least one bioactive agent is present as one or more segments that are coupled to an elastomeric body (see, for example, Figures 4A to 4E). In certain embodiments, an elastomeric body further comprises a thermoplastic support ring. In certain embodiments, a biocompatible polymeric material may Petition 870250115808, dated 12 / 16 / 2025, p. 15 / 67 12 / 50 to be molded onto a thermoplastic support ring to form an elastomeric body. Molding can be done by overmolding, insert molding, or 3D printing. In certain embodiments, a thermoplastic support ring can be used to mount one or more segments containing bioactive agents onto it and thus connect the elastomeric body to one or more segments. In certain embodiments, one or more segments containing bioactive agents have a total external surface area of about 50–1000 mm². In certain embodiments, one or more segments containing bioactive agents have a total external surface area of about 200–600 mm². In certain embodiments, one or more segments containing bioactive agents have a total external surface area of about 380–600 mm². In certain embodiments, one or more segments containing bioactive agents have a total external surface area of about 380–400 mm².In certain embodiments, one or more segments containing bioactive agents have a total external surface area of approximately 400–500 mm². In certain embodiments, one or more segments containing bioactive agents have a total external surface area of approximately 394 mm². In certain embodiments, one or more segments containing bioactive agents have a total external surface area of approximately 425 mm². In certain embodiments, one or more segments containing bioactive agents have a total external surface area of approximately 473 mm². In certain embodiments, one or more segments containing the bioactive agent have an arc of approximately 40–60 degrees. In certain embodiments, one or more segments containing the bioactive agent have an arc of approximately 45–50 degrees.
[0021] In certain embodiments, at least one bioactive agent is placed in a permeable reservoir. Petition 870250115808, dated 12 / 16 / 2025, p. 16 / 67 13 / 50 as a solution, where at least one bioactive agent is released by diffusion through the reservoir to a vaginal region. In certain embodiments, an elastomeric body has orifices and openings where the openings can be used as reservoirs.
[0022] In certain embodiments, at least one bioactive agent is a copper-containing agent. Examples of copper-containing agents include, but are not limited to, metallic copper, copper alloys, copper salts, or any combination thereof. Copper salts may be copper sulfate, copper gluconate, copper amino acid chelates, and copper oxide. In certain embodiments, at least one bioactive agent is copper metal. In certain embodiments, at least one bioactive agent may comprise one or more copper salts as a solid. In certain embodiments, at least one bioactive agent may comprise one or more copper salts and one or more non-copper spermicides as a solid. The solid may be incorporated within an elastomeric ring and diffuse into the vaginal region, cervical region, and endometrial region when positioned in the vaginal region. In certain embodiments, at least one bioactive agent may comprise one or more copper salts in solution.In certain embodiments, at least one bioactive agent may comprise one or more copper salts and one or more non-copper spermicides in solution. The solution may be stored in a permeable reservoir that allows both the copper salts and the non-copper spermicides to diffuse into the vaginal region when positioned there. Examples of non-copper spermicides include, but are not limited to, nonoxynol-9, menfegol, boric acid, citric acid, zinc sulfate, potassium permanganate, and benzalkonium chloride. Petition 870250115808, dated 12 / 16 / 2025, page 17 / 67 14 / 50
[0023] In certain embodiments, at least one bioactive agent may additionally comprise one or more vaginal health-promoting agents, which may be vaginal probiotics, prebiotics, acidifying agents, and a combination thereof. The vagina harbors a normal population of microorganisms (i.e., vaginal microbiota) that help protect against infections by pathogenic bacteria, fungi, or other organisms that may enter the vagina. Administration of certain prebiotics and / or vaginal microbiota may promote the growth of microorganisms and therefore be beneficial in promoting or maintaining a healthy vaginal environment. In addition, maintaining an acidic pH (below 4.5) with acids may also protect the vagina against infections.Examples of vaginal microbiota strains that may be administered to a subject, as presented herein, include, but are not limited to, Lactobacillus crispatus, Lactobacillus iners, Lactobacillus jensenii, Lactobacillus gasseri, Lactobacillus acidophilus, Lactobacillus rhamnosus, Lactobacillus reuteri, and Bifidobacterium longum. Examples of prebiotics include, but are not limited to, lactitol, inulin, lactulose, and oligosaccharides. Examples of acidifying agents include, but are not limited to, lactic acid, acetic acid, ascorbic acid, aspartic acid, citric acid, folic acid, potassium sorbate, and boric acid. In certain embodiments, the acidifying agent is lactic acid. In certain embodiments, at least one bioactive agent may be released at a controlled rate over a predetermined period of time.
[0024] In certain embodiments, one or more vaginal health-promoting agents may be mixed with the spermicidal bioactive agents described above. In certain Petition 870250115808, dated 12 / 16 / 2025, page 18 / 67 In 15 / 50 modalities, one or more vaginal health-promoting agents are separated from the spermicidal bioactive agents. For example, one or more vaginal health-promoting agents may be stored in reservoirs separate from the reservoirs where the spermicidal bioactive agents are stored.
[0025] In certain embodiments, a contraceptive device described herein is positioned in the vaginal region of the female reproductive system for a period of one week to one year (or less than two weeks in emergency contraception embodiments), after which the contraceptive device is removed from the vaginal region of the female reproductive system for a period of one to three weeks or more. In certain embodiments, a contraceptive device is inserted into the vaginal region of the female reproductive system for a period of one week, after which the contraceptive device is removed from the vaginal region of the female reproductive system for a period of one week. In certain embodiments, a contraceptive device is inserted into the vaginal region of the female reproductive system for a period of two weeks, after which the contraceptive device is removed from the vaginal region of the female reproductive system for a period of one week.In certain embodiments, a contraceptive device is inserted into the vaginal region of the female reproductive system for a period of two weeks, after which the contraceptive device is removed from the vaginal region of the female reproductive system for a period of two weeks. In certain embodiments, a contraceptive device is inserted into the vaginal region of the female reproductive system for a period of three weeks, after which the contraceptive device is removed from the vaginal region of the female reproductive system for a period of one week. Petition 870250115808, dated 12 / 16 / 2025, page 19 / 67 16 / 50 to two weeks. In certain embodiments, a contraceptive device is positioned in the vaginal region of the female reproductive system for a period of one month, after which the contraceptive device is removed from the vaginal region of the female reproductive system for a period of one to three weeks or more. In certain embodiments, a contraceptive device is installed in the vaginal region of the female reproductive system during ovulation. In certain embodiments, a contraceptive device is installed in the vaginal region of the female reproductive system as needed. In certain embodiments, a contraceptive device is installed in the vaginal region of the female reproductive system for a period of one year, after which the contraceptive device is removed from the vaginal region of the female reproductive system for a period of one to three weeks or more. In certain embodiments, a contraceptive device can be reused monthly for up to one year.For example, a contraceptive device may be inserted into the vaginal region of the female reproductive system for one to three weeks per month, after which the contraceptive device may be removed for one to three weeks and may be reused the following month for about one to three weeks, or other similar intervals that would be immediately foreseen by one skilled in the art, in view of the disclosure contained herein.
[0026] The contraceptive device described here can be used before sexual intercourse for prophylactic contraception. The contraceptive device described here is as effective as the copper IUDs of the prior art, but has far fewer side effects than copper IUDs due to its distance from the uterus and duration of use. Petition 870250115808, dated 12 / 16 / 2025, p. 20 / 67 17 / 50 Specifically, unlike copper IUDs, the device described here is not placed inside the uterus and remains in the body for 5 years or more. The contraceptive device described here also does not have the side effects associated with hormonal methods, as it does not contain hormones.
[0027] A contraceptive device described herein can be used, such as the copper IUD, up to 120 hours after sexual intercourse for emergency contraception. For example, a contraceptive device can be used within approximately 15 minutes, 30 minutes, 1 hour, 2 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 120 hours, or at any time interval in between. Due to the ease of insertion and the low risk of a foreign body response (such as those that arise with copper IUDs inserted into the uterus, for example), the modalities described in this document provide advantages compared to prior art devices, which do not provide accessible emergency contraception using copper ions. For example, and as described further below, the copper IUD is not readily accessible as an emergency contraceptive device, at least because its insertion requires a clinical setting and the supervision of a medical professional, such as a physician.Since the contraceptive device described here can be inserted into the vaginal region of the female reproductive system by a subject in need of it and does not require a clinical setting, it is more accessible and convenient than copper IUDs.
[0028] In certain embodiments, one or more vaginal health-promoting agents may be co-administered with a device described herein. For example, they may be administered before, during, and after the use of a device. Petition 870250115808, dated 12 / 16 / 2025, page 21 / 67 18 / 50 described herein to maintain and restore a healthy vaginal environment. In certain embodiments, one or more vaginal health-promoting agents are administered after removal of a device described herein to restore a healthy vaginal environment.
[0029] The terminology used in this document is intended to describe specific modalities only and should not be interpreted as limiting. As used in the Descriptive Report and the accompanying claims, the singular forms a, “an” and the include plural referents, unless the context clearly indicates otherwise.
[0030] In the present disclosure, the female reproductive system or uterine reproductive system may refer to the reproductive system of any person who has the capacity to become pregnant. As used herein, the female reproductive system is not limited to individuals who identify as women, being recognized as a common term for the physiological system that supports fertility and reproduction, including organs such as the uterus, ovaries, fallopian tubes, vagina, and cervix.
[0031] In the present disclosure, “spermiostatic” or “spermicide” may mean a substance that provides contraceptive benefits by acting by inhibiting or reducing the normal cellular function of a spermatozoon, for example, by inhibiting the motility and / or survival of a spermatozoon, thereby preventing the ability of a spermatozoon to fertilize an egg. As used herein, spermiostatic or spermicidal substances may be used alone or in combination with other contraceptives to prevent unwanted pregnancy. Petition 870250115808, dated 12 / 16 / 2025, page 22 / 67 19 / 50
[0032] In the present disclosure, a “bioactive agent” may refer to a substance that has an effect on the cellular functions or behaviors of a living organism. A bioactive agent may be a metal, a chemical compound, a pharmaceutical (e.g., a drug), and an enzyme.
[0033] In the present disclosure, “Pearl Index” refers to a statistical measure of pregnancy rate, calculated using the following formula: Pearl Index = (Number of pregnancies x 12) x 100 / (Number of women in the study x Duration of the study in months). The lower the Pearl Index, the lower the pregnancy rate and the better the contraceptive method.
[0034] In the present disclosure, “μg / g” is equivalent to “μg / ml,” since 1 g of a sample corresponds to approximately 1 ml; “wet weight” refers to the weight of samples collected without any prior treatment, and “dry weight” refers to the weight of samples dried before analysis.
[0035] In the present disclosure, an “elastomer” or an “elastomeric material” may mean a natural or synthetic polymer that has elastic properties, that is, capable of returning to its original shape after the removal of an applied force.
[0036] In the present disclosure, thermoplastic may mean any substance that has the properties of a plastic material when heated (e.g., soft, flexible, moldable, etc.) and that hardens or solidifies when cooled.
[0037] In the present disclosure, molding may mean attaching one object onto another object and overmolding may mean an injection molding technique for manufacturing a single component composed of two or Petition 870250115808, dated 12 / 16 / 2025, page 23 / 67 20 / 50 more materials, such as molding one thermoplastic material onto another thermoplastic material.
[0038] As used herein, “exposed surface” and “external surface” are interchangeable, and “foreign body response” and “foreign body reaction” are interchangeable.
[0039] As used herein, “copper”, “metallic copper” and “pure metallic copper” are interchangeable and may refer to a material containing at least 99.9% copper.
[0040] As used herein, “about” means encompassing variations of ±30%, ±20%, ±10%, ±5%, ±1%, ±0.5%, ±0.1%, or any variations that are appropriate for the performance anticipated by one skilled in the art. The numerical ranges mentioned herein will be immediately understood by one skilled in the art, based on the context in which they are used in the disclosure contained herein.
[0041] Example technical solutions of this disclosure are described below, with reference to the accompanying drawings. Similar reference numbers may have been used in different figures to denote similar components.
[0042] Figure 1A illustrates an example of a female reproductive system 100 in which the methods and devices described herein can be applied, according to the embodiments of the present disclosure. The system 100 has been simplified to facilitate understanding and reference in the embodiments presented herein. The main internal organs of the female reproductive system 100 include the uterus 110, ovaries 120, fallopian tubes 130, vagina (or vaginal tract) 140, and cervix 150. The cervix 150 is the narrow lower portion of the uterus 110 that projects into the vagina 140. In the fertilization process, sperm travel along the tract. Petition 870250115808, dated 12 / 16 / 2025, p. 24 / 67 21 / 50 vaginal 140 and enter the uterus 110 through the cervix 150. The cervix produces mucous secretions that become thin and stringy under the influence of high systemic concentrations of estrogen in the plasma, and these secretions can facilitate the movement of spermatozoa through the reproductive tract. An unfertilized egg (e.g., ovum) stored in one of the two ovaries 120 is released into a respective fallopian tube 130 and travels towards the uterus 110. Typically, the egg can be fertilized by a spermatozoon in the fallopian tube 130 and the fertilized egg reaches the uterus where it can implant in the inner wall of the uterus 110 (e.g., endometrium). After implantation, the fertilized egg can become an embryo and then develop into a fetus.
[0043] Figure 1B illustrates that when a copper IUD is implanted, copper ions concentrate in the uterus 110, shown as dashed shadows, and when a device described herein is positioned, copper ions are concentrated in the vaginal and cervical region, shown as dotted shadows, and in the uterus 110.
[0044] Figure 1C illustrates the positions of a copper IUD, Nuvaring®, and a device described herein when placed in the female reproductive system. A copper IUD is placed inside the uterus 110, a Nuvaring® ring is placed deep in the cervical region and a device described herein may be placed in the vaginal region.
[0045] Figure 2 shows an exemplary contraceptive device according to the description contained herein. A contraceptive device is an intravaginal ring 200 comprising a torus-shaped elastomeric body. Petition 870250115808, dated 12 / 16 / 2025, page 25 / 67 22 / 50 210.
[0046] Figure 3 shows an exemplary intravaginal ring according to certain embodiments of the present disclosure. The intravaginal ring 300 has a torus-shaped elastomeric body 310 and multiple copper-containing inclusions 320. In certain embodiments, the copper-containing inclusions 320 comprise a copper-containing bioactive agent, such as metallic copper or a copper alloy. In certain embodiments, the copper-containing inclusions 320 are dotted on the surface of the elastomeric body 310 and dispersed throughout the elastomeric body 310, so that the entire surface of the copper-containing inclusions 320 is exposed. When the intravaginal ring 300 is positioned in the vaginal or cervical region of the female reproductive system 100, the copper-containing inclusions 320 are exposed to the environment in the vaginal region and, as a result, copper ions are released in the vaginal region and also in the cervical and endometrial regions.In certain embodiments, the inclusions containing copper 320 are incorporated into the elastomeric body 310 and dispersed throughout the elastomeric body 310, so that the inclusions containing copper 320 are partially exposed or not exposed. When the intravaginal ring 300 is positioned in the vaginal region of the female reproductive system 100, copper ions pass through the elastomeric body 310 and are released into the vaginal region. The size, quantity, and spacing of the inclusions containing copper 320, whether dotted or incorporated into the body 310, are not particularly limited, but can be oriented to optimize the total surface area and positioning of the inclusions containing copper 320, to control a dosage of the copper-containing substance to be released optimally (e.g., Petition 870250115808, dated 12 / 16 / 2025, page 26 / 67 23 / 50 therefore, conferring contraceptive activity) very close to the cervix, thus providing improved contraception compared with previous devices that are unable to position the released copper in this region. In certain embodiments, the total exposed surface area of the copper-containing inclusions is about 50–1000 mm2, about 200–600 mm2, about 380–600 mm2, about 380–400 mm2, about 400–500 mm2, about 394 mm2, about 473 mm2, or about 425 mm2. The total exposed surface area, the unexposed inclusions, and a combination thereof can be adjusted to control the copper ion release rates that can be predicted by one skilled in the art, in view of the present disclosure herein.
[0047] Figures 4A to 4E show examples of intravaginal rings according to certain embodiments of the present disclosure. The intravaginal rings shown in Figures 4A to 4E (400) have a torus-shaped elastomeric body 410 and one or more copper-containing segments 420. The one or more copper-containing segments 420 are connected or coupled to the elastomeric body 410. The outer surface of one or more copper-containing segments 420 may be aligned with the outer surface of the elastomeric body 410 (for example, as described in relation to Figure 5). When the intravaginal ring 400 is positioned in the vaginal region of the female reproductive system 100, the copper-containing segments 420 are exposed to the environment of the region and, as a result, copper ions are released into the vaginal region, as well as into the cervical and endometrial regions by diffusion.The outer surface of one or more segments containing copper 420 may be coated with a permeable membrane, whose outer surface... Petition 870250115808, dated 12 / 16 / 2025, page 27 / 67 24 / 50 is aligned with the outer surface of the elastomeric body 410. The permeable membrane can be used to control the release rates of copper ions.
[0048] In certain embodiments, the one or more segments containing copper 420 have a total external surface area of about 50 - 1000 mm2. In certain embodiments, the one or more segments containing copper 420 have a total external surface area of about 200 - 600 mm2. In certain embodiments, the one or more segments containing copper 420 have a total external surface area of about 380 - 600 mm2. In certain applications, one or more segments containing copper 420 have a total external surface area of approximately 380 - 400 mm2. In certain embodiments, the one or more segments containing approximately 420 copper have a total external surface area of approximately 400-500 mm2. In certain embodiments, the one or more segments containing 420 copper have a total external surface area of approximately 394 mm2. In certain embodiments, the one or more segments containing 420 copper have a total external surface area of approximately 425 mm2. In certain embodiments, the one or more segments containing 420 copper have a total external surface area of approximately 473 mm2. In certain embodiments, the one or more segments containing 420 copper have an arc of approximately 40-60 degrees. In certain embodiments, the one or more segments containing 420 copper have an arc of approximately 45-55 degrees. In certain embodiments, the one or more segments containing 420 copper have an arc of approximately 45-50 degrees. In certain configurations, one or more segments containing 420 copper have an arc of approximately 45 degrees.In certain embodiments, one or more segments containing 420 copper have an arc of approximately 50 degrees. In certain embodiments, Petition 870250115808, dated 12 / 16 / 2025, p. 28 / 67 25 / 50 The total external surface area of one or more segments containing copper and the total external surface area of the elastomeric body are present in a ratio between about 1:100 and 1:1, a ratio between about 1:50 and 1:1, a ratio between about 1:20 and 1:1, a ratio between about 1:10 and 1:1, a ratio between about 1:5 and 1:1, and any range between these values. In a specific embodiment, the intravaginal ring 400 has a transverse diameter of about 4 mm, an external diameter of about 54 mm, a single segment containing copper 420 with an arc of about 45 degrees, and an external surface area of the single segment containing copper 420 of about 473 mm2. In another specific embodiment, the intravaginal ring 400 has a transverse diameter of approximately 4.8 mm, an outer diameter of approximately 55 mm, and an outer surface area of the single segment containing copper 420 of approximately 394 mm2.In another specific embodiment, the intravaginal ring 400 has a transverse diameter of approximately 6.35 mm, an external diameter of approximately 55 mm, a single segment containing copper 420 with an arc of approximately 50 degrees, and an external surface area of the single segment containing copper 420 of approximately 425 mm². The intravaginal ring 400 may comprise one segment containing copper 420 (as in Figure 4A), two segments containing copper 420 (as in Figure 4B), three segments containing copper 420, four segments containing copper 420 (as in Figure 4C), six segments containing copper 420 (as in Figure 4D), 12 segments containing copper 420 (as in Figure 4E), or more, or any number between these. It is understood that, although each segment containing copper 420 in Figures 4B-4E is shown as having the same size, each segment containing copper 410 of an intravaginal ring 400 may have different sizes. O. Petition 870250115808, dated 12 / 16 / 2025, page 29 / 67 26 / 50 size and the number of segments containing copper 420 can be determined based on the desired dosage or the rate of copper ion release in the vaginal, cervical, and endometrial regions and / or the desired level of flexibility of the intravaginal ring 400 to facilitate insertion and retention of the intravaginal ring in the desired position. In certain embodiments, the segments containing copper 420 can be arranged in an alternating pattern, for example, alternating with sections of the elastomeric body 410, based on a desired level of flexibility of the intravaginal ring 400 to facilitate insertion.
[0049] Figure 5A shows a cross-sectional view of the intravaginal ring 400 of Figure 4A. The intravaginal ring 400 comprises an elastomeric body 410 and one or more copper-containing segments 420. In some embodiments, each copper-containing segment 420 may be an arched, tubular component with a hollow cavity 422 extending the entire length of the copper-containing segment 420 and projections 424 at each end to secure the copper-containing segment 420 to the elastomeric body 410. In some embodiments, the projections 424 may be barbs of sufficient length to grip the inner diameter of the elastomeric body 410 and seal the connection. In some embodiments, the copper-containing segments 420 are made of copper metal. In certain embodiments, the segment containing copper 420 in Figure 5A can be constructed from a rigid or thermoplastic material that has properties that allow bonding with an elastomeric material.In some applications, the segment containing 420 copper may be constructed from a rigid material, the surface of which may be coated with copper. Petition 870250115808, dated 12 / 16 / 2025, page 30 / 67 27 / 50
[0050] In some embodiments, the intravaginal ring 400 can be assembled by inserting the barbs 424 into the elastomeric body 410, where the barbs 424 have sufficient lengths to grip the inner diameter of the elastomeric body 410 and seal the connection. In some embodiments, the intravaginal ring 400 can be assembled by molding (e.g., overmolding), where the elastomeric body 410 is molded directly onto the projections 424, thus coupling the elastomeric body 410 directly to the copper-containing segment 420. In certain embodiments, the projections 424 may extend to sufficient lengths to provide sufficient surface areas for coupling to the elastomeric body 410. In some embodiments, during molding, the hollow cavity 422 may be filled with an elastomeric material to provide mechanical locking of the copper-containing segment 420 with the elastomeric body 410.The segment containing copper 420 can be fixed by other means that would be immediately foreseen by one skilled in the art, in view of the disclosure contained herein.
[0051] Figure 5B is a perspective view of the segment containing copper 420, according to embodiments of the present disclosure. The segment containing copper 420 comprises a metallic or thermoplastic core, the outer surfaces of which are coated with a layer of copper 426. The metallic or thermoplastic core may be located between the two projections 424. The thickness of the copper 426 layer may be determined based on the desired dosage or the rate of copper ion release in the vaginal, cervical, and endometrial regions. For example, the copper 426 layer may have a thickness between about 0.1 mm and 1 cm, between about 0.5 mm Petition 870250115808, dated 12 / 16 / 2025, page 31 / 67 28 / 50 and 5 mm, between about 1 mm and 5 mm, between about 1 mm and 2.5 mm, or any value between these. In some embodiments, the metallic or thermoplastic core may first be coated with the copper layer 426 and then coupled to the elastomeric body 410 by inserting protrusions 424 into the elastomeric body 410. In some embodiments, the protrusions 424 may include friction-inducing elements, for example, barbs, to help secure and retain the thermoplastic core in the elastomeric layer. Alternatively, the elastomeric body 410 may be molded into the projections 424 of the metallic or thermoplastic core, and then the copper layer 426 is coated over the core. The copper coating and the copper layer may be a copper alloy or pure metallic copper, among other copper compositions described herein.
[0052] Figure 5C is a cross-sectional view of the copper-containing segment 420 of Figure 5B, according to embodiments of the present disclosure. The copper-containing segment 420 comprises a hollow cavity 422 extending the entire length of the copper-containing segment 420, and projections 424 extending from each end of the copper-containing segment 420.
[0053] Figure 6A shows a side view of the intravaginal ring of Figure 4A, according to the embodiments of the present disclosure. The intravaginal ring 400 comprises the elastomeric body 410 and one or more copper-containing segments 420. The one or more copper-containing segments 420 can be coupled to the elastomeric body 410 by means of a metallic or thermoplastic support ring 428.
[0054] In certain embodiments, one or more segments containing copper 420 have a surface area Petition 870250115808, dated 12 / 16 / 2025, page 32 / 67 29 / 50 total external surface area of approximately 50 - 1000 mm2. In certain embodiments, one or more segments containing copper 420 have a total external surface area of approximately 200 - 600 mm2. In certain embodiments, one or more segments containing copper 420 have a total external surface area of approximately 380 - 600 mm2. In certain embodiments, one or more segments containing copper 420 have a total external surface area of approximately 380 - 400 mm2. In certain embodiments, one or more segments containing copper 420 have a total external surface area of approximately 400 - 500 mm2. In certain embodiments, one or more segments containing copper 420 have a total external surface area of approximately 394 mm2. In certain embodiments, one or more segments containing copper 420 have a total external surface area of approximately 425 mm2. In certain embodiments, one or more segments containing copper 420 have a total external surface area of approximately 473 mm2.In certain embodiments, one or more segments containing copper 420 have an arc of approximately 40–60 degrees. In certain embodiments, one or more segments containing copper 420 have an arc of approximately 45–55 degrees. In certain embodiments, one or more segments containing copper 420 have an arc of approximately 45–50 degrees. In certain embodiments, one or more segments containing copper 420 have an arc of approximately 45 degrees. In certain embodiments, one or more segments containing copper 420 have an arc of approximately 50 degrees. In one specific embodiment, the intravaginal ring 400 has a transverse diameter of approximately 4 mm, an outer diameter of approximately 54 mm, a single segment containing copper 420 with an arc of approximately 45 degrees, and an external surface area of the single segment containing copper 420 of approximately 473 mm². In another embodiment... Petition 870250115808, dated 12 / 16 / 2025, p. 33 / 67 In a specific embodiment, the 30 / 50 intravaginal ring 400 has a transverse diameter of approximately 4.8 mm, an outer diameter of approximately 55 mm, and an external surface area of the single segment containing copper 420 of approximately 394 mm2. In another specific embodiment, the intravaginal ring 400 has a transverse diameter of approximately 6.35 mm, an outer diameter of approximately 55 mm, a single segment containing copper 420 with an arc of approximately 50 degrees, and an external surface area of the single segment containing copper 420 of approximately 425 mm2. In yet another specific embodiment, the intravaginal ring 400 has a transverse diameter of approximately 6.35 mm, an outer diameter of approximately 55 mm, two segments containing copper 420, each with an arc of approximately 50 degrees, and a total external surface area of the two segments containing copper 420 of approximately 425 mm2.In yet another specific embodiment, the intravaginal ring 400 has a transverse diameter of approximately 4 mm, an outer diameter of approximately 54 mm, two segments containing copper 420, each with an arc of approximately 45 degrees, and a total external surface area of the two segments containing copper 420 of approximately 473 mm2. In certain embodiments, the total external surface area of one or more segments containing copper and the total external surface area of the elastomeric body are present in a ratio of approximately 1:100. 1:1, a ratio between approximately 1:50 and 1:1, a ratio between approximately 1:20 and 1:1, a ratio between approximately 1:10 and 1:1, a ratio between approximately 1:5 and 1:1, and any range between these values.
[0055] Figure 6B shows a cross-sectional view of the intravaginal ring of Figure 6A, according to examples of the present disclosure. The intravaginal ring 400 comprises the elastomeric body 410 which is molded into a ring. Petition 870250115808, dated 12 / 16 / 2025, p. 34 / 67 31 / 50 of support 428 and one or more segments containing copper 420. The support ring 428 can be metallic or thermoplastic. In certain embodiments, the support ring 428 is thermoplastic. In certain embodiments, the support ring 428 has a ring body and two enlarged ends, where the ring body provides the support structure upon which the elastomeric body can be molded and the two enlarged ends allow the segments containing copper 420 to couple to the elastomeric body 410. In certain embodiments, the support ring 428 has a ring body and two ends with the same size as the ring body.
[0056] In certain embodiments, the elastomeric body 410 is molded onto the body of the support ring 428, followed by the insertion of the barbs 424 of the copper-containing segment 420 into the enlarged ends of the support ring 428 to ensure the connection between the elastomeric body 410 and the copper-containing segment 420. In certain embodiments, the copper-containing segment 420 can be mounted onto the support ring 428 by inserting each end of the support ring 428 into the hollow cavity 422 of the copper-containing segment 420 before molding the elastomeric body 410 onto the support ring 428. In certain embodiments, the copper-containing segment 420 can be mounted onto the support ring 428 by inserting each end of the support ring 428 into the metallic or thermoplastic core positioned between the two projections 424 before molding the elastomeric body 410 onto the support ring. 428. The segment containing copper 420 can be made of metallic copper and copper alloys.In certain embodiments, the segment containing copper 420 is made of copper metal. In certain embodiments, the copper is Cu 101, which contains approximately 99.99%. Petition 870250115808, dated 12 / 16 / 2025, page 35 / 67 32 / 50 copper. In certain versions, the elastomeric body is made of silicone.
[0057] Figure 7A shows an exemplary embodiment of an intravaginal ring, according to embodiments of the present disclosure. The intravaginal ring 700 has an elastomeric body 710, one or more orifices 720 in the elastomeric body 710, and a copper-containing agent within the elastomeric body. The elastomeric body 710 is made of biocompatible polymers. In certain embodiments, the elastomeric body 710 is a silicone elastomer that may be permeable or impermeable. The intravaginal ring 700 is shown in an exemplary configuration with 13 circular orifices 720; however, the orifices 720 may be incorporated into the intravaginal ring 700 in other shapes and quantities. For example, 720 holes can be oval, triangular, diamond-shaped, square, rectangular, trapezoidal, pentagonal, hexagonal, or octagonal, or any combination thereof. The number of 720 holes can be one, two, three, four, five, six, seven, or more.When the intravaginal ring 700 is positioned in the vaginal region of the female reproductive system 100, the orifices 720 allow a copper-containing agent to come into contact with the fluids in the region and release copper ions into the vaginal region, the cervical region, and the endometrial region.
[0058] Figure 7B shows an exemplary copper-containing agent within the intravaginal ring 700 of Figure 7A, according to embodiments of the present disclosure. In certain embodiments, a copper-containing agent is a copper wire shown as 750 without openings 760. The total external surface area of the copper wire can vary between about 50 mm2 and 1000 mm2. Petition 870250115808, dated 12 / 16 / 2025, page 36 / 67 33 / 50 between approximately 200 mm² and 600 mm², between approximately 380 mm² and 600 mm², between approximately 380 mm² and 400 mm², between approximately 400 mm² and 500 mm², and any ranges between these. In certain embodiments, a thermoplastic structure 750 is used with one or more openings 760 that fit into the orifices 720, as shown in Figure 7B. The one or more openings 760 may be reservoirs for storing a copper-containing agent, which may be copper metal, a copper alloy, a solid copper salt, or a copper salt solution. In certain embodiments, copper metal, a copper alloy, a solid copper salt, or a combination thereof may be filled into the one or more openings 760 and have external surfaces exposed to the vaginal environment when positioned in that region.The total external surface area of the copper metal, copper alloy, and solid copper salts can vary between about 50 mm² and 1000 mm², between about 200 mm² and 600 mm², between about 380 mm² and 600 mm², between about 380 mm² and 400 mm², between about 400 mm² and 500 mm², and any ranges between these. In certain embodiments, a copper salt solution within a permeable membrane can be stored in one or more openings. In some embodiments, a resulting dosage of about 50 mm² and 1000 mm² of an exposed copper-containing agent can be used.
[0059] In certain embodiments, a copper wire may be placed inside the elastomeric body 710 during its preparation or inserted through the orifices 720 after the elastomeric body 710 has been prepared. In certain embodiments, the elastomeric body 710 is molded onto the thermoplastic structure 750 and a copper-containing agent is filled into one or more openings 760. Petition 870250115808, dated 12 / 16 / 2025, p. 37 / 67 34 / 50
[0060] In some embodiments, a contraceptive device of the present disclosure further comprises a barrier, such as a diaphragm device. In certain embodiments, a contraceptive device may be a ring that is not a barrier device like a diaphragm device. In certain embodiments, the contraceptive device described herein is not a barrier device. In certain embodiments described herein, the contraceptive device is not saucer-shaped. In certain embodiments of the contraceptive device described herein, the device does not form a barrier over the opening of the cervix. In some embodiments, a barrier may comprise a flexible body that is positioned in the vaginal region of the female reproductive system 100 to provide a physical barrier against the migration and fertilization of spermatozoa and a bioactive agent comprising copper, which is incorporated into the flexible body.In some forms, a bioactive agent is a copper wire wrapped along the outer edge of the flexible body, with one surface exposed to the vaginal environment, releasing copper ions to hinder sperm migration and fertilization. The barrier provides the added benefit of combining a physical barrier that prevents sperm from passing through the cervix with the spermicidal effect of copper, providing highly effective contraception.
[0061] Figure 8 illustrates a method of using a contraceptive device described herein. The method 800 begins in step 802, where the contraceptive device is inserted into the vaginal region of the female reproductive system 100 by a subject in need of it and / or with the help of a Petition 870250115808, dated 12 / 16 / 2025, page 38 / 67 35 / 50 device applicator. In certain embodiments, a contraceptive device described herein can be easily inserted by a subject in need thereof, rather than by a clinician or in a clinical setting, unlike conventional copper IUDs, which require administration in a clinical setting, which can be painful and unsuitable for use as emergency contraception. The contraceptive device described herein can be used for planned contraception and / or for emergency contraception. The contraceptive device described herein can be inserted into the vaginal region before sexual intercourse or within 120 hours after sexual intercourse and can remain in place for a period of two weeks, three weeks, or one year, or any period in between.
[0062] In step 804, in response to exposure to an environment of the vaginal region of the female reproductive system 100, a copper-containing bioactive agent may be released at a specific rate in the vaginal region, cervical region, and endometrial region to produce a spermicidal or spermiostatic effect on spermatozoa that may be present in the vaginal and / or cervical region. In certain embodiments, a copper-containing bioactive agent is released at a controlled rate and / or at a controlled dosage. In certain embodiments, a contraceptive device described herein is configured to continuously release the copper-containing bioactive agent during the predetermined period, for example, providing a reliable contraceptive method for the entire predetermined duration. In certain embodiments, the predetermined duration ranges from one day to four weeks or more.
[0063] In certain forms, the concentrations of Petition 870250115808, dated 12 / 16 / 2025, page 39 / 67 36 / 50 copper in the uterus is about 3.0 - 20 pg / g or about 3.0 - 20.0 pg / ml (dry weight) from day 3 to year 5 after insertion of a device described herein. For example, the concentration of copper in the uterus (dry weight) may be approximately 3.9 to 4.2 pg / g, 3.5 pg / g, 3.9 pg / g, 4.0 pg / g, 4.1 pg / g, 4.2 pg / g, 4.3 pg / g, 4.4 pg / g, 4.5 pg / g, 5.0 pg / g, 5.5 pg / g, 6.0 pg / g, 6.5 pg / g, 7.0 pg / g, 7.5 pg / g, 8.0 pg / g, 8.5 pg / g, 9.0 pg / g, 9.5 pg / g, 10.0 pg / g, 10.5 pg / g, 11.0 pg / g, 11.5 pg / g, 12.0 pg / g, 12.5 pg / g, 13.0 pg / g, 13.5 pg / g, 14.0 pg / g, 14.5 pg / g, 15.0 pg / g, 15.5 pg / g, 16.0 pg / g, 16.5 pg / g, 17.0 pg / g, 17.5 pg / g, 18.0 pg / g, 18.5 pg / g, 19.0 pg / g, 19.5 pg / g, 20.0 pg / g or any value in between. In certain embodiments, copper concentrations in the uterus (dry weight) on day 3 after insertion of a device described herein are approximately 3.9 to 10.0 pg / g. For example, copper concentrations in the uterus on day 3 after insertion of a device described herein may be approximately 3.9 to 4.2 pg / g, 3.9 pg / g, 4.0 pg / g, 4.1 pg / g, 4.2 pg / g, 4.3 pg / g, 4.4 pg / g, 4.5 pg / g, 5.0 pg / g, 5.5 pg / g, 6.0 pg / g, 6.5 pg / g, 7.0 pg / g, 7.5 pg / g, 8.0 pg / g, 8.5 pg / g, 9.0 pg / g, 9.5 pg / g, 10.0 pg / g, or any value in between.
[0064] In certain embodiments, copper concentrations in the uterus may be about 0.5 to 5.0 pg / g (dry weight) or about 0.5 to 5.0 pg / ml (wet weight) from day 3 until removal of the device (e.g., one month, two months, three months, six months, one year, two years, three years, four years, or up to about five years or more) after insertion of a device described herein. The concentration of copper in the uterus (wet weight) can be approximately 0.8 to 1.8 pg / g, 0.9 to 1.8 pg / g, 10.5 pg / g, 0.6 pg / g, 0.7 pg / g, 0.8 pg / g, 0.9 pg / g, 1.0 pg / g, 1.01 pg / g, 1.2 pg / g, 1.3 pg / g, 1.04 pg / g, 1.5 pg / g, 1.6 Petition 870250115808, dated 12 / 16 / 2025, p. 40 / 67 37 / 50 gg / g, 1.7 gg / g, 1.8 gg / g, 1.9 gg / g, 2.0 gg / g, 2.5 gg / g, 3.0 gg / g, 3.5 gg / g, 4.0 gg / g, 4.5 gg / g, 5.0 gg / g, or any value between these. In certain embodiments, copper concentrations in the uterus on day 3 after insertion of a device described herein are approximately 0.9 to 3.0 gg / g (wet weight). For example, copper concentrations in the uterus on day 3 after insertion of a device described herein may be approximately 0.8 to 1.8 g / g, 0.9 to 1.8 g / g, 0.9 g / g, 1.0 g / g, 1.1 g / g, 1.2 g / g, 1.3 g / g, 1.4 g / g, 1.5 g / g, 1.6 g / g, 1.7 g / g, 1.8 g / g, 1.9 g / g, 2.0 g / g, 2.5 g / g, 3.0 g / g, or any value in between.
[0065] It is understood that the concentration of copper in the uterus will increase after the insertion of a copper-containing device, as described herein, but that the copper concentration may reach an equilibrium level, as presented herein, that maintains an effective concentration of copper in the cervical region, vaginal region, and / or uterus during the period that the contraceptive device described herein remains in the subject's vaginal region. In certain embodiments, the concentration of copper in the uterus increases for approximately one week, two weeks, three weeks, six months, one year, two years, three years or more after the insertion of a device described herein.
[0066] In certain embodiments, a device described herein may release copper for approximately one week to five years. For example, a device described herein may release copper for approximately one week, two weeks, three weeks, one month, two months, six months, one year, two years, three years, four years, five years, or any period in between. Petition 870250115808, dated 12 / 16 / 2025, p. 41 / 67 38 / 50
[0067] In certain embodiments, a device described herein may have a Pearl Index of about 0.8-5, about 0.8-1.5, about 0.9-1.4, about 0.8-1.3, about 1.0-1.5, about 0.9-1.1, about 0.8-1.0, about 1.0-3.5, about 0.9-4.5, about 1.8-5.0, or about 1.1-1.2. For example, a device described herein may have a Pearl Index of about 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 2, 3, 4, 5, or any value between these.
[0068] In step 806, in response to the end of the predetermined duration or, alternatively, in response to the user's determination that the use of the contraceptive device is no longer desired, the contraceptive device may be removed from the vaginal region of the female reproductive system by the subject in need. In some embodiments, the contraceptive device may be removed from the vaginal region with the aid of a device applicator or a removal tool. In certain embodiments, the contraceptive device is easily removed by the subject in need, rather than by a clinical professional or in a clinical setting.
[0069] Although the present disclosure presents methods and processes with steps in a particular order, one or more steps of the methods and processes may be omitted or altered as appropriate. One or more steps may occur in a different order than that in which they are described, as appropriate.
[0070] The present disclosure may be incorporated in other specific forms without departing from the subject matter of the claims. The example embodiments described should be regarded in all respects as merely illustrative. Petition 870250115808, dated 12 / 16 / 2025, page 42 / 67 39 / 50 and non-restrictive. Selected features from one or more of the modalities described above may be combined to create alternative modalities not explicitly described, with the appropriate features for such combinations being understood within the scope of this disclosure.
[0071] All values and subranges within the revealed ranges are also revealed. Furthermore, although the systems, devices, and processes revealed and presented herein may comprise a specific number of elements / components, the systems, devices, and assemblies may be modified to include more or fewer of these elements / components. For example, although any one of the revealed elements / components may be referenced as being singular, the embodiments revealed herein could be modified to include a plurality of such elements / components. The subject matter described herein is intended to encompass and incorporate all pertinent technological changes. Examples Example 1: Animal study to evaluate the effectiveness of a contraceptive device.
[0072] A contraceptive device illustrated in Figure 4A was studied for its effectiveness in animals by determining copper concentrations in vaginal fluids and the uterus. The study was conducted by Charles River Laboratories. The device has an outer diameter of approximately 55 mm and a cross-sectional diameter of approximately 4.8 mm (3 / 16"). The copper segment in the device has an exposed surface area of approximately 394 mm². The device was boiled at 100 °C (+ / - 1 °C) in deionized water for Petition 870250115808, dated 12 / 16 / 2025, page 43 / 67 40 / 50 approximately 5 minutes and sealed in sterile bags before the study. Female sheep (S. Ovis aries, Dorset x Rideau Arcott hybrid lineage, supplied by Bakerstone) were used due to their physiological and anatomical similarities to human reproductive systems. Two young adult sheep (aged between 2 and 4.5 years) and weighing between 70 and 75 kg were selected for the study.
[0073] Prior to the study, both sheep underwent environmental acclimation for 21 days, during which time the sheep were housed together in an environment with a concrete floor covered with wood chips and fed pellets (ENVIGO Teklad Ruminant Food or equivalent) and tap water. To induce estrus and ovulation, the sheep received an intramuscular injection of Estrumate (prostaglandin; 1 ml) eleven days before the study (Day -11) and then with Estrumate (prostaglandin, 1 ml) and Novormon (equine chorionic gonadotropin, 2 ml) one day before the study (Day -1). Between day 11 and day -1, the sheep were habituated to being handled in a sling for at least 3 sessions during the estrus synchronization period.
[0074] On the first day of the study (Day 0), a contraction device was inserted into each sheep and positioned firmly horizontally, as high as possible in the cranial vagina to prevent slippage. Prior to insertion, vaginal fluid samples and vaginal swabs were collected as baseline samples for assessing vaginal copper concentration. Vaginal fluids were collected in sterile tubes by contacting the vaginal walls with the sterile tubes. Vaginal samples were collected by gently sliding swabs into the vaginal area. Petition 870250115808, dated 12 / 16 / 2025, page 44 / 67 41 / 50 upper part of the vagina, touching the vaginal walls with the tips of the swabs and gently rotating them at least 5 times clockwise to absorb as much moisture as possible. On Day 1 (between 24 and 48 hours after insertion), Day 2 (between 48 and 72 hours after insertion), and Day 3 (between 72 and 80 hours after insertion), vaginal fluids and samples were collected from both sheep daily using the methods described above. The tubes and swabs were weighed before and after collection to determine the net weight of the vaginal fluids and vaginal smears collected. The vaginal fluids and smears collected were flash-frozen in dry ice and stored at -80 °C until copper concentration analysis.
[0075] On Day 3, an endometrial biopsy was performed on a sheep via laparoscopy. Under anesthesia, an incision was made at the base of the right uterine horn using a Halstead hemostatic forceps, and a sterile swab with a flocculated tip was introduced through it to collect endometrial secretions. After collection, the swab was placed in a tube. Both the tube and the swab were weighed before and after collection to determine the net weight of the endometrial smear sample collected. The endometrial sample was flash-frozen on dry ice and then stored in a freezer at -80 °C. After removal of the swab, an endometrial biopsy was performed with a pipette to collect endometrial secretions from the right and left uterine horns. Each sample was placed in a separate, appropriately identified sterile tube, placed on dry ice, and stored in a freezer at -80 °C. Petition 870250115808, dated 12 / 16 / 2025, page 45 / 67 42 / 50
[0076] Copper concentrations in vaginal fluids, vaginal smears, and endometrial samples were measured using inductively coupled plasma mass spectrometry (ICPMS). For pipelle-obtained endometrial biopsy samples, copper concentrations were initially measured based on the wet weight of the samples (using the samples collected as they were) and then measured based on the dry weight of the samples (after drying the collected samples prior to analysis). Each sample was measured three times, and copper concentrations were reported as mean ± standard deviation. The results are shown in Tables 1 to 3 below.
[0077] Table 1 shows that copper concentrations in vaginal samples and vaginal fluids increased significantly each day from day 0 to day 3, and on day 3 the vagina had a very high copper concentration. The table shows that on day 3, the right uterine horn had copper concentrations of approximately 0.9 pg / g (wet weight) and 4.2 pg / g (dry weight), while the left uterine horn had copper concentrations of approximately 1.04 pg / g (wet weight) and 3.9 pg / g (dry weight). Table 3 shows that on day 3, the right uterine horn had copper concentrations of approximately 0.89 pg / g (wet weight) and the left uterine horn had copper concentrations of approximately 1.74 pg / g (wet weight). It has been reported that a copper IUD with a total copper surface area of 175 mm2 resulted in a copper concentration of approximately 0.67 pg / g (wet weight) in the human uterus between the first and sixth month after IUD insertion.It has also been reported that (i) this copper IUD has a contraceptive efficacy of 92.2%, (ii) another copper IUD with the same. Petition 870250115808, dated 12 / 16 / 2025, pp. 46 / 67 43 / 50 total surface area of copper has a Pearl Index of 0.96, (iii) NOVA-T® (i.e., a copper IUD) with a total copper surface area of 200 mm2 shows a pregnancy rate of 1.26 / 100 patient-years (i.e., also effective in contraception), and (iv) a copper concentration of 3.9 pg / g (dry weight) or less in the uterus can be effective for contraception. The contraceptive device described herein produces uterine copper concentrations of at least about 0.90 pg / g (wet weight, thus exceeding the limit of 0.67 pg / g wet weight considered an effective copper concentration, from conventional copper IUDs) and 3.9 pg / g (dry weight) on day 3, indicating that the contraceptive device described herein is highly effective for contraception both as a preventive device and for emergency contraception.Considering the copper concentration achieved on day 3 in the uterus and vagina, the contraceptive device described here can be used for emergency contraception and is more effective than the reported copper IUDs, since the latter take much longer (i.e., at least one month) to release such a high concentration of copper, and this high concentration of copper is present only in the uterus, not in the vagina. Petition 870250115808, dated 12 / 16 / 2025, pp. 47 / 67 44 / 50 Table 1: Copper concentrations in vaginal fluids of sheep Day 0 Day 1 Day 2 Day 3 Copper concentration in vaginal smear (g / smear) 0.041±0.00 03 0.539±0.01 3 1.03±0.01 10.62±0.09 Copper concentration (g / g of vaginal fluid) 1.60±0.01 * - 57.5±0.6 136±1 *: The copper concentration on Day 1 was not listed because the sample failed the QC test. Table 2: Copper concentrations in endometrial biopsy samples from ewes on day 3 Dry weight (gg / g) Wet weight (gg / g) Dry weight (g) Wet weight (g) Moisture (%)* Left horn 3.9±0.1 1.04±0.03 0.0176 0.0654 73.1 Right horn 4.2±0.1 0.90±0.03 0.0139 0.0651 78.6 Moisture (%) refers to the moisture content in wet samples. Dry samples had no moisture content. Petition 870250115808, dated 12 / 16 / 2025, pp. 48 / 67 45 / 50 Table 3: Copper concentrations in endometrial biopsy smear samples on day 3 from sheep. Concentration of Cu (pg / g) Mass of Cu (pg / smear) Uterine fluid (g) Right horn 0.89±0.03 43±1 0.0483 Left horn 1.74±0.07 76±3 0.0435 Example 2: Human study to evaluate the effectiveness of a contraceptive device.
[0078] The effectiveness of the contraceptive device used in Example 1 was evaluated in humans by determining copper concentrations in vaginal fluids and in the uterus.
[0079] On the start day of the study, the contraction device was inserted into the vagina of a biological female. On each day from day 3 and on day 3 after device insertion, a vaginal swab was collected by inserting the soft tip of a sterile cotton swab (from an STI testing kit) into the vagina approximately 2 inches (5 cm) beyond the vaginal opening and rotating the swab for 10 to 30 seconds to ensure the swab touched the vaginal walls so that moisture was absorbed by the swab. On day 3 after device insertion, an endometrial biopsy was performed by a licensed gynecologist, following standard procedures for collecting an endometrial biopsy sample. Copper concentrations in the vaginal and uterine samples were analyzed using ICPMS. The results are shown in Table 4. Petition 870250115808, dated 12 / 16 / 2025, pp. 49 / 67 46 / 50
[0080] The results show that (i) copper concentrations in the vagina increased from day 3 to day 5, which is consistent with the results obtained in the vagina of sheep and (ii) on day 5, the uterus showed copper concentrations of approximately 1.12 gg / g (wet weight) and 4 gg / g (dry weight), similar to the copper concentrations in the uterus of sheep on day 3 of Example 1. The results further demonstrate the effectiveness of a device described herein for emergency contraception due to the copper concentrations on day 3 and can be used for prophylactic contraception by virtue of its long-lasting release. Table 4: Copper concentrations in human vaginal smears and endometrial biopsy samples Copper concentration in vaginal smear (gg / smear) Copper concentration in vaginal smear (gg / ml) Copper concentration in endometrial biopsy (gg / g) Day 3 3.04+0.04 152±2 1.12+0.02 (wet weight; having a moisture content of 72%); 4.02+0.06 (dry weight) Day 5 3.47+0.14 174±7 - Example 3: Animal study to evaluate the safety, tolerability and efficacy of a contraceptive device
[0081] A contraceptive device illustrated in Figure 4A or Figure 4B will be studied for its safety, tolerability, and efficacy in animals. Sheep aged between Petition 870250115808, dated 12 / 16 / 2025, pp. 50 / 67 47 / 50 Sheep aged 1-4.5 years, weighing between 45-100 kg, and with 0-2 previous pregnancies will be obtained in January of the study year. The study will be conducted from March to June, as these are the typical breeding months. Sheep will be freely fed with feed and water at equal frequencies and kept in enclosed facilities with a 12 / 12 hour light / dark cycle for six weeks before the start of the study and throughout its duration. A total of 20 sheep will be randomly divided into two groups, where group A will receive a contraceptive device and group B will be the control group. The vaginal dimensions of each sheep will be measured to determine the size of the contraceptive device to be inserted.
[0082] On day 1 of the study, 5 sheep from Group A will be anesthetized and a contraceptive device will be inserted into each of their vaginal regions. On day 2, all sheep will be induced into estrus, either (i) by treatment with progesterone followed by exposure to a ram after a minimum interval of 6 weeks, or (ii) by treatment with progesterone followed by serum gonadotropin from a pregnant mare. On day 5 of the study, frozen ram semen will be thawed in a water bath at 37°C for 30 seconds, after which sperm motility and morphology will be analyzed under a microscope to ensure that the ram semen is suitable for use. 60 hours after estrus induction, all sheep will be artificially inseminated with ram semen. On day 35, all sheep will be evaluated for pregnancy. On day 36, the non-pregnant ewe will be induced into estrus and, 60 hours later, will be artificially inseminated with the ram's semen again. Petition 870250115808, dated 12 / 16 / 2025, pp. 51 / 67 48 / 50
[0083] The effectiveness of a contraceptive device described herein for emergency contraception will also be evaluated. 24 hours after insemination, another five sheep from Group A will be anesthetized and have a contraceptive device inserted. 72 hours after insemination, another five sheep from Group A will be anesthetized and have a contraceptive device inserted. 120 hours after insemination, the last five sheep from Group A will be anesthetized and have the contraceptive device inserted.
[0084] On day 71, all sheep will be assessed for pregnancy using a serum test. From day 1 to day 71, vaginal fluids will be collected to determine copper concentrations. Throughout the study, sheep in Group A will be monitored for signs of adverse effects, such as infection and irritation, through weekly veterinary vaginal examinations. Example 4: the safety, tolerability, and effectiveness of a contraceptive device in humans.
[0085] A contraceptive device described and illustrated herein in Figure 4A or Figure 4B will be evaluated in a pivotal clinical study for its safety, tolerability, and efficacy.
[0086] A total of 200 individuals aged between 18 and 40 years will participate in the study. All participants have the potential to become pregnant, good general health, regular menstrual cycles between 24 and 32 days, willingness to become pregnant if the device fails, willingness to discontinue the use of any current contraceptive method, willingness to have regular sexual intercourse throughout the cycles, and the capacity to give consent. Petition 870250115808, dated 12 / 16 / 2025, pp. 52 / 67 49 / 50 reported. The study will be conducted in accordance with the ethical principles described in the Tri-Agency Policy Statement: Ethical Conduct in Research Involving Human Subjects (TCPS 2).
[0087] Each participant will insert a contraceptive device into the vagina and keep it in place for three weeks of the menstrual cycle, removing it on day 26 of the menstrual cycle and keeping it in place until day five of the following menstrual cycle. Data will be collected at various times throughout the study period. Before the start of the study, baseline demographic and medical information will be collected from each participant. During the study, participants will be scheduled for regular follow-up appointments at two weeks, one month, two months, three months, five months, and seven months, which will include clinical assessments, laboratory tests, and completion of questionnaires to assess pregnancy rates, safety, tolerability, and any adverse events.Specific data collected will include serum copper and pregnancy tests, swabs to check vaginal pH, vaginal copper concentration, and overall vaginal tissue health, responses to questionnaires on ease of insertion, comfort, irritation, partner comments (if applicable), ease of removal, and any concerns about use during sexual intercourse. Descriptive statistics will be used to summarize demographic characteristics and baseline data. Safety and tolerability will be assessed through analysis of the incidence and severity of adverse events reported by participants. Pregnancy rates will be documented and analyzed appropriately. Example 5: Effectiveness of emergency contraception in humans Petition 870250115808, dated 12 / 16 / 2025, pp. 53 / 67 50 / 50
[0088] A contraceptive device described and illustrated herein in Figure 4A or Figure 4B will be evaluated for its effectiveness in emergency contraception compared to a copper IUD.
[0089] Individuals aged 18 to 40 years will participate in the study. Participants will be divided into two groups. One group will insert a contraceptive device described herein, and the other group will insert the copper IUD into the vagina within 5 days of sexual intercourse. After insertion, copper concentrations in the vagina and uterus of the subject will be determined in both groups, from day 1 to day 5. Data will also be collected and analyzed, including pregnancy tests and swabs to check vaginal pH. Petition 870250115808, dated 12 / 16 / 2025, pp. 54 / 67
Claims
1 / 5 CLAIMS 1. A contraceptive device configured for insertion into the vagina of a female reproductive system of a subject, wherein the contraceptive device is characterized by comprising: an elastomeric body in the shape of a torus; and at least one bioactive agent having spermicidal or spermiostatic properties coupled to the elastomeric body, wherein the contraceptive device is configured to release an effective amount of at least one bioactive agent into the vaginal region, cervical region and endometrial region of the female reproductive system when the contraceptive device is positioned in the vaginal region of the female reproductive system.
2. Contraceptive device, according to claim 1, characterized in that at least one bioactive agent is a copper-containing agent.
3. Contraceptive device, according to claim 2, characterized in that the copper-containing agent is copper, a copper alloy, a copper salt, or a combination thereof.
4. Contraceptive device, according to claim 3, characterized in that the copper-containing agent is copper.
5. Contraceptive device, according to claim 4, characterized in that the elastomeric body is dotted with copper as a plurality of inclusions and the copper surface is in contact with the environment of the vaginal region of the female reproductive system. Petition 870250103188, dated 11 / 11 / 2025, page 6 / 14 2 / 5 6. Contraceptive device, according to claim 1, characterized in that at least one bioactive agent additionally comprises one or more vaginal health-promoting agents.
7. Contraceptive device, according to claim 6, characterized in that one or more vaginal health-promoting agents are selected from the group consisting of acidifying agents, vaginal microbiota, prebiotics, or a combination thereof.
8. Contraceptive device, according to claim 7, characterized in that the acidifying agent is lactic acid.
9. Contraceptive device, according to claim 7, characterized by the vaginal microbiota being Lactobacillus crispatus, Lactobacillus iners, Lactobacillus jensenii, Lactobacillus gasseri, Lactobacillus acidophilus, Lactobacillus rhamnosus, Lactobacillus reuteri, Bifidobacterium longum or a combination thereof.
10. A method for emergency contraception characterized by comprising: inserting an emergency contraceptive device into the vaginal region of a female reproductive system after sexual intercourse, wherein the emergency contraceptive device comprises a torus-shaped elastomeric body and at least one bioactive agent having spermicidal or spermiostatic properties coupled to the elastomeric body.
11. Method according to claim 10, characterized in that at least one bioactive agent is a copper-containing agent. Petition 870250103188, dated 11 / 11 / 2025, page 7 / 14 3 / 5.
12. Method according to claim 11, characterized in that the copper-containing agent is copper, a copper alloy, a copper salt, or a combination thereof.
13. Method according to claim 12, characterized in that the copper-containing agent is copper.
14. Method according to claim 13, characterized in that the copper is coupled to the elastomeric body as one or more segments.
15. Method according to claim 14, characterized in that the elastomeric body has a cross-sectional diameter of about 3.0 - 10 mm and an outer diameter of about 30 - 90 mm.
16. Method according to claim 14, characterized in that one or more copper segments have an arc of about 40-60 degrees.
17. Method according to claim 14, characterized in that one or more copper segments have a total outer surface area of about 50–1000 mm².
18. Method, according to claim 10, characterized in that the emergency contraceptive device is co-administered with one or more vaginal health-promoting agents.
19. Method according to claim 18, characterized in that one or more vaginal health-promoting agents are selected from the group consisting of acidifying agents, vaginal microbiota, prebiotics, or a combination thereof.
20. Method according to claim 19, characterized in that the acidifying agent is lactic acid. Petition 870250103188, dated 11 / 11 / 2025, p. 8 / 14 4 / 5 21. Method, according to claim 19, characterized in that the vaginal microbiota are Lactobacillus crispatus, Lactobacillus iners, Lactobacillus jensenii, Lactobacillus gasseri, Lactobacillus acidophilus, Lactobacillus rhamnosus, Lactobacillus reuteri, Bifidobacterium longum or a combination thereof.
22. Method according to claim 10, characterized in that at least one bioactive agent additionally comprises one or more vaginal health-promoting agents.
23. Method, according to claim 10, characterized in that the emergency contraceptive device is positioned in the vaginal region of a female reproductive system within 120 hours of sexual intercourse and for a duration of less than two weeks, after which the contraceptive device is removed from the vaginal region of a female reproductive system for a duration of one to three weeks or more weeks.
24. Method, according to claim 10, characterized in that the emergency contraceptive device is positioned in the vaginal region of a female reproductive system within 120 hours of sexual intercourse and for a duration of one week to one year, after which the contraceptive device is removed from the vaginal region of a female reproductive system for a duration of one to three weeks.
25. Method, according to claim 10, characterized in that the emergency contraceptive device is positioned in the vaginal region of a female reproductive system within 48 hours of sexual intercourse for emergency contraception.
26. Method according to claim 10, Petition 870250103188, dated 11 / 11 / 2025, page 9 / 14 5 / 5 characterized in that the emergency contraceptive device is positioned in the vaginal region of a female reproductive system within 24 hours of sexual intercourse for emergency contraception.
27. A method for planned contraception characterized by comprising: inserting a contraceptive device into the vaginal region of a female reproductive system before sexual intercourse, wherein the contraceptive device comprises a torus-shaped elastomeric body and at least one bioactive agent having spermicidal or spermiostatic properties coupled to the elastomeric body.
28. Method according to claim 27, characterized in that the contraceptive device is positioned in the vaginal region of a female reproductive system before sexual intercourse and for a duration of between one week and one year, after which the contraceptive device is removed from the vaginal region of a female reproductive system for a duration of one to three weeks or more.
29. Method for producing a contraceptive device characterized by comprising: providing a thermoplastic support ring; molding an elastomeric material over the thermoplastic support ring to form a torus-shaped elastomeric body having two ends; providing an arched, tubular copper metal containing two burrs; and inserting the burrs into each end of the elastomeric body. Petition 870250103188, dated 11 / 11 / 2025, page 10 / 14
